Zafirlukast , ≥99% , 107753-78-6

Synonym(s):
N-[3-[[2-Methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]carbamic acid cyclopentyl ester

CAS NO.：107753-78-6

Empirical Formula: C31H33N3O6S

Molecular Weight: 575.68

MDL number: MFCD00864775

PRODUCT Properties

• Melting point: 139°C
• Density: 1.32±0.1 g/cm3(Predicted)
• storage temp.: room temp
• solubility: DMSO: ≥28mg/mL
• pka: 4.94±0.10(Predicted)
• form: solid
• color: White or pink
• Merck: 14,10108
• Stability: Stable for 2 years as supplied. Protect from exposure to moisture. Solutions in DMSO may be stored at -20°C for up to 3 months.

Description and Uses

Accolate was launched in Ireland, Finland and the US for treatment of asthma. Prepared via an eight step synthesis from methyl 3-methoxy-4- methylbenzoate, zafirlukast acts as a LTD₄ antagonist and is the first compound of a new class of drugs. LTC₄, LTD₄ and LTE₄ were determined to be the constituents of the slow-reacting substance of anaphylaxis (SRS-A) which was found to induce asthma effects (bronchoconstriction, increased vascular permeability resulting in edema, cellular infiltration of airway tissues and decreased mucociliary transport). Thus an inhibitor of their synthesis would at least attenuate these symptoms. Zafirlukast binds to the CysLT receptor LT-1 and blocks the effect of LTC₄, LTD₄ and LTE₄. The drug is an oral twice daily formulation that reversed an LTD₄ challenge, attenuated the response of platelet-activating factor (PAF), an allergen and cold air challenge and exercise-induced asthma.

antiasthmatic;leukotriene receptor antagonist (LTRA)

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H315-H319-H335
• Precautionary statements: P261-P305+P351+P338
• WGK Germany: 3
• RTECS: FB3966200
• HS Code: 2935.90.6000